Chemiluminescence Immunoassay Market Size, Share & Trends Analysis By Product (Consumables, Instruments and Software & Services), By Application (Cardiology, Therapeutic Drug Monitoring, Oncology, Endocrinology, Autoimmune Disease, Infectious Disease and Others), By End-User (Clinical Laboratories, Hospitals, Pharmaceutical & Biotechnology Companies and Others) - Global Industry Analysis, Trends, Segment Forecasts, Regional Outlook 2020 - 2027

The global chemiluminescence immunoassay market size was valued at US$ 5.97 billion in 2019 and predicted to register a compound annual growth rate (CAGR) of around 7.6% during period 2020 to 2027.

The global chemiluminescence immunoassay market size is expected to reach of around US$ 10.6 billion by 2027.

Growth Factors         

Diagnostic technology is budding rapidly, and over the last decade, considerable progress has been made in the identification of antibodies, progressively impending this sort of diagnostic to that of automated clinical chemistry laboratory. The number of tests integrating chemiluminescence immunoassay Analyzers practices is estimated to magnify on account of technological advancements in disease diagnosis, upsurge in demand for treatment monitoring and precautionary diagnosis. Subsequently, requirement for high throughput facilities are also increasing. Furthermore, large-scale laboratories are capturing benefit of service and quality constraints confronted by small and mid-volume laboratories to seize a bigger chunk of the market by means of CLIA methods.

Companion diagnostics comprise assays or tests proposed to support healthcare providers in taking treatment decisions for patients on the basis of finest response to therapy. The co-development of companion diagnostics along with therapeutic products has the latent to meaningfully modify the drug development process and commercialize drug candidates by getting safer drugs with improved therapeutic effectiveness cost-effectively and quickly. With an increase in the demand for high-priced specialist therapies and safer drugs, the market for companion diagnostics is expected to showcase a high growth potential.The Novel coronavirus epidemic is expected to influence market projections for the chemiluminescence immunoassays market. This is due to its possible application in eliminating the disease. Research is underway for the development of the peptide-based magnetic CLIA for serological diagnosis of the COVID-19 virus. This is a noteworthy development since this is the second diagnostic test afterwards real-time RT-PCR, which is the only existing laboratory test to check probable cases of contamination.

Application Insights

Numerous applications of chemiluminescence immunoassay market comprises of disorders, endocrine infectious diseases, oncology, cardiovascular disorders, hepatitis and retrovirus, allergy, drug discovery & development autoimmunity, and others. Endocrine gathered considerable market share in terms of revenue in 2019 and it is predicted to reflect this tendency throughout the estimate period. Foremost influences accountable for the governance of this application segment are incessant inventions in test offerings and extensive product offerings of chief and local manufacturers.

Product Insights

Among different product segments analyzed in this research study, consumables segment garnered substantial share more than 70% of the total market revenue generated in 2019. This segment is predicted to hold its domination over the prediction period. This growth can be credited to augmented requirement for consumables including stains and reagents in the area of endocrinology, therapeutic drug monitoring, and disease analysis. 

End-user Insights

In terms of several end-users, hospitals grasp majority of the market chunk and reported prime revenue share of more than 35% in 2019. This governance is credited to the cumulative need for chemiluminescence immunoassay solutions in hospitals and intensifying hospital visits on account of mounting occurrence of infectious diseases and cancer. Correspondingly, the growing hospitalization owed to outburst of novel coronavirus is anticipated to increase the requirement for chemiluminescence immunoassay solutions in the hospital segment. Snowballing amount of applications of automated CLIA analyzers in oncology, therapeutic drug monitoring, and companion diagnostics and emergence of integrated modules of automated CLIA analyzers are projected to fuel the growth of hospitals segment throughout the estimate period.

Regional Insights

North America seized the substantial market stake globally in 2019 and is projected to mirror this trend during the assessment period. Significant influences backing to its governance are the existence of established healthcare infrastructure, high acceptance of cutting-edge chemiluminescence immunoassay solutions, and snowballing pervasiveness of chronic diseases among others. Additionally, augmented availability of novel CLIA systems in the U.S. on account of existence of crucial market participants like Beckman Coulter, Inc., Abbott Laboratories, Roche and DiaSorinis further likely to subsidize the growth of the market in the North America.

Asia Pacific is prospective to be an extremely profitable market for the chemiluminescence immunoassay analyzers market and it is anticipated to develop at a rapid growth rate throughout the estimate period. Huge population base and escalation in occurrence of infectious and chronic diseases augments requirement for diagnostic testing in the APAC. Besides, promising government initiative to progress healthcare infrastructure is expected to supplement the growth of the market.

Key Companies & Market Share Insights

Extension of test offerings in ground-breaking ailment diagnosis areas and inventions in integrated immunoassay platforms are significant strategies of players involved in the CLIA marketplace. Certain substantial participants operating in the chemiluminescence immunoassay market include:

  • Hoffmann-La Roche AG
  • Siemens Healthineers
  • Abbott Laboratories
  • DiaSorin S.p.A.
  • Ortho Clinical Diagnostics
  • Immunodiagnostic Systems
  • Beckman Coulter Inc.
  • Inova Diagnostics, Inc.
  • Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
  • Maccura Biotechnology Co., Ltd
  • Others

Segments Covered in the Report

This research report includes complete assessment of the market with the help of extensive qualitative and quantitative insights, and projections regarding the market. This report offers breakdown of market into prospective and niche sectors. Further, this research study calculates market revenue and its growth trend at global, regional, and country from 2016 to 2027.This report includes market segmentation and its revenue estimation by classifying it on the basis of product, application, end-usersand region as follows:

By Product

    • Consumables
    • Instruments
      • Automated
      • Semi-automated
    • Software & Services

By Application

  • Cardiology
  • Therapeutic Drug Monitoring
  • Oncology
  • Endocrinology
  • Autoimmune Disease
  • Infectious Disease
  • Others

By End-use

  • Clinical Laboratories
  • Hospitals
  • Pharmaceutical & Biotechnology Companies
  • Others

By Regional Outlook

  • North America
    • U.S.
    • Canada
  • Europe
    • U.K.
    • Germany
    • Italy
    • France
    • Rest of EU
  • Asia Pacific
    • China
    • India
    • Japan
    • Southeast Asia
    • Rest of APAC
  • Middle East & Africa
    • GCC
    • North Africa
    • South Africa
    • Rest of Middle East and Africa
  • Latin America
    • Argentina
    • Mexico
    • Brazil
    • Rest of Latin America
Request for Customize Report
Precedence offers custom market research services that help clients to get information on their business scenario required.

FAQ's

How much is the chemiluminescence immunoassay market worth?
The global chemiluminescence immunoassay market size was valued at US$ 5.97 billion in 2019 and expected to reach of around US$ 10.6 billion by 2027.
The global chemiluminescence immunoassay market is predicted to register a compound annual growth rate (CAGR) of around 7.6% during period 2020 to 2027.
North America led the global market in 2019 with largest market share on account of snowballing occurrence of chronic diseases and better-qualityand upgraded healthcare infrastructure.
Hospitals segment reported highest share of the revenue generated in 2019. This growth is attributed to snowballing number of uses of automated CLIA analyzers in oncology, therapeutic drug monitoring and companion diagnostics .
Enhancements are predictable during years to come with the progress of novel analytical platforms like 2D resolution for chemiluminescence multiplex immunoassay andflow-injection chemiluminescent immunoassay and magnetic nanoparticles chemiluminescence immunoassay. This would probably outcome in supplementary increases in the clinical effectiveness of antibody tests. Influences like intensifying pervasiveness of infectious and chronic diseases, technological progressions in POC testing products, and mounting patient consciousness of POC testing are few of the chief influences fueling the need of immunoassay depending upon POC testing and swift testing around the world. The chemiluminescence immunoassay analyzers market is presently a thriving one, as there has been upsurge in requirement f
Chemiluminescent immunoassay (CLIA) is a variation of the biochemical technique employed in immunology named standard enzyme immunoassay. They can also be utilized as diagnosis tools in medicine and further finds application in several other plentiful industries. The foremost benefit of this technology comprises sensitivity and its aptitude to be unpretentious by signals in the background. Correspondingly, the analyzers working below this principle are easier in operation and design.

PROCEED TO BUY

   USD 4999
   USD 7999

ASK FOR SAMPLE

No cookie-cutter, only authentic analysis – take the 1st step to become an Precedence client

Get a Sample
Address: Apt 1408 1785 Riverside Drive Ottawa, ON, K1G 3T7, Canada
Call: +1 774 402 6168
Email: sales@precedenceresearch.com